Collecting Dutch data on radiation treatment for brain and nerve-related tumours
Collects treatment data from adults with brain tumours receiving proton or photon radiation.
Key facts
- Who runs it
- Maastricht Radiation Oncology
- Where
- Netherlands3 sites in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Proton Therapy Research Infrastructure- ProTRAIT- Neuro-oncology
- Status
- Recruiting
- People taking part
- 1,500 people, planned
- Started
- 1 Jan 2018
- Expected to end
- 1 Jan 2035
- Type of study
- Observational
- Treatments tested
- ProTRAIT
- Record updated
- 13 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a brain tumour that has a good outlook (median survival over 10 year). They must be getting proton therapy, where the dose to the brain is lower than with photon therapy.
- Age
- 18 years and older
- Sex
- All sexes
- Disease stage
- Brain tumours with a favorable prognosis (median survival > 10 year). Daily activity must be good: ECOG 0 - 1 or Karnofsky 80 - 100. No or only minimal problems with memory and thinking.
- Biomarker or test result
- A planning study must show that proton therapy gives a lower dose than photon therapy (≥5% on supratentorial brain dose or hippocampi).
Main reasons for not taking part
- People who cannot have chemotherapy
- People who can have stereotactic radiotherapy (highly focused radiation)
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- All brain tumors with a favorable prognosis (median survival > 10 year)
- Age ≥ 18 years
- ECOG performance status 0 - 1 / Karnofsky performance status 80 - 100
- No - minimal neurocognitive impairment
- Dosimetrical gain of protontherapy relative to photontherapy (≥5% on supratentorial brain dose or hippocampi)
- Informed consent
Who cannot take part
- Not eligible for chemotherapy
- Eligible for stereotactic radiotherapy
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The first proton therapy treatments in the Netherlands have taken place in 2018. Due to the physical properties of protons, proton therapy has tremendous potential to reduce the radiation dose to the healthy, tumour-surrounding tissues. In turn, this leads to less radiation-induced complications, and a decrease in the formation of secondary tumours. The Netherlands has spearheaded the development of the model-based approach (MBA) for the selection of patients for proton therapy when applied to prevent radiation-induced complications. In MBA, a pre-treatment in-silico planning study is done, comparing proton and photon treatment plans in each individual patient, to determine (1) whether there is a significant difference in dose in the relevant organs at risk (ΔDose), and (2) whether this dose difference translates into an expected clinical benefit in terms of NormalTissue Complication Probabilities (ΔNTCP). To translate ΔDose into ΔNTCP, NTCP-models are used, which are prediction models describing the relation between dose parameters and the likelihood of radiation-induced complications. The Dutch Society for Radiotherapy and Oncology (NVRO) setup the selection criteria for proton therapy in 2015, taking into account toxicity and NTCP. However, NTCP-models can be affected by changes in the irradiation technique. Therefore, it is paramount to continuously update and validate these NTCP-models in subsequent patient cohorts treated with new techniques. In ProTRAIT, a Findable, Accessible, Interoperable and Reusable (FAIR)data infrastructure for both clinical and 3D image and 3D dose information has been developed and deployed for proton therapy in the Netherlands. It allows for a prospective, standardized, multi-centric data from all Dutch proton and a representative group of photon therapy patients.
Treatments tested
- ProTRAIT
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Proton Therapy Research Infrastructure- ProTRAIT- Neuro-oncology
- Plain-language title
- Collecting Dutch data on radiation treatment for brain and nerve-related tumoursGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 13 October 2026